DrugPatentWatch Database Preview
Drugs in Development Information for ENMD-1198
What is the drug development status for ENMD-1198?
ENMD-1198 is an investigational drug.
There have been 8 clinical trials for ENMD-1198.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2010.
The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are CASI Pharmaceuticals, Inc., University Health Network, Toronto, and University of Colorado, Denver.
There are two US patents protecting this investigational drug and six international patents.
Summary for ENMD-1198
| US Patents | 2 |
| International Patents | 6 |
| US Patent Applications | 3 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2010-04-01) |
| Vendors | 8 |
Recent Clinical Trials for ENMD-1198
| Title | Sponsor | Phase |
|---|---|---|
| A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma | CASI Pharmaceuticals, Inc. | Phase 2 |
| A Study of ENMD-2076 in Ovarian Clear Cell Cancers | University Health Network, Toronto | Phase 2 |
| Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma | University Health Network, Toronto | Phase 2 |
Clinical Trial Summary for ENMD-1198
Top disease conditions for ENMD-1198
Top clinical trial sponsors for ENMD-1198
US Patents for ENMD-1198
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ENMD-1198 | Start Trial | Antiangiogenic agents | EntreMed, Inc. (Rockville, MD) | Start Trial |
| ENMD-1198 | Start Trial | Methods of treating disease states using antiangiogenic agents | EntreMed, Inc. (Rockville, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ENMD-1198
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ENMD-1198 | Australia | 2005222934 | 2024-03-12 | Start Trial |
| ENMD-1198 | Canada | 2558014 | 2024-03-12 | Start Trial |
| ENMD-1198 | European Patent Office | 1756139 | 2024-03-12 | Start Trial |
| ENMD-1198 | Japan | 2007529426 | 2024-03-12 | Start Trial |
| ENMD-1198 | World Intellectual Property Organization (WIPO) | 2005089256 | 2024-03-12 | Start Trial |
| ENMD-1198 | World Intellectual Property Organization (WIPO) | 2008011005 | 2024-03-12 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
